

IN THE CLAIMS

Please amend claims 28, 29, and 30 as follows.

Please cancel claims 24 and 26 without prejudice to subsequent revival.

28. (once amended) A recombinant nucleic acid according to Claim 25 or 27, further comprising a fusion partner.

29. (once amended) An expression vector, comprising a recombinant nucleic acid according to Claims 25 or 27 operably linked to a regulatory sequences recognized by a host cell transformed with the nucleic acid.

30. (once amended) A host cell comprising a nucleic acid according to Claims 25 or 27.

REMARKS

Claims 25 and 27-33 are pending in the application and have been examined. Appendix A provides the "Version with Markings to Show Changes Made." All pending claims are provided in Appendix B for the Examiner's convenience.

Rejection under 35 USC § 112, first paragraph: enablement

Claims 24-33 were rejected as allegedly lacking enablement. Applicants respectfully note that the pending claims are compound claims directed to a nucleic acid. Furthermore, Applicants have amended the claims to recite a Mkinase nucleic acid having a sequence of SEQ ID NO:1 or encoding an Mkinase protein of SEQ ID NO:2. Such nucleic acid compounds are useful for numerous applications, as described in the specification on page 4, 5, and 31. MPEP § 2164.01(c) describes the enablement standard for compound and composition claims as follows: